Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Return on Sales (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Return on Sales for 10 consecutive years, with 1.26% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales rose 6.0% year-over-year to 1.26%, compared with a TTM value of 1.31% through Sep 2025, down 147.0%, and an annual FY2024 reading of 2.54%, down 2700.0% over the prior year.
  • Return on Sales was 1.26% for Q3 2025 at Spero Therapeutics, down from 0.12% in the prior quarter.
  • Across five years, Return on Sales topped out at 1.51% in Q4 2022 and bottomed at 122.0% in Q1 2022.
  • Average Return on Sales over 5 years is 19.62%, with a median of 3.59% recorded in 2021.
  • The sharpest move saw Return on Sales surged 46808bps in 2021, then tumbled -11936bps in 2022.
  • Year by year, Return on Sales stood at 1.78% in 2021, then surged by 185bps to 1.51% in 2022, then plummeted by -2190bps to 31.54% in 2023, then soared by 91bps to 2.75% in 2024, then soared by 54bps to 1.26% in 2025.
  • Business Quant data shows Return on Sales for SPRO at 1.26% in Q3 2025, 0.12% in Q2 2025, and 2.36% in Q1 2025.